Clinical Trials Logo

Upper Gastrointestinal Bleeding clinical trials

View clinical trials related to Upper Gastrointestinal Bleeding.

Filter by:

NCT ID: NCT06350864 Recruiting - Clinical trials for Upper Gastrointestinal Bleeding

HFNC Versus Conventional Oxygen Therapy in Prolonged Upper Gastrointestinal Endoscopy in the ICU

Start date: January 20, 2024
Phase: N/A
Study type: Interventional

Conventional supplemental oxygen therapy (COT) during upper gastrointestinal (UGI) endoscopy via nasal catheter is considered the standard practice in maintenance of oxygenation and prevention of hypoxia. However, it is still unclear if this oxygen delivery method is optimal in a prolonged (more than 15 minutes) procedure in patients admitted to the ICU. Because of shortage of data in this concern, this prospective, randomized, controlled clinical trial study will aim to evaluate and compare the efficacy of high-flow nasal cannula (HFNC) oxygen therapy versus COT in patients who will undergo prolonged either diagnostic or therapeutic UGI endoscopy in the intensive care unit (ICU) .

NCT ID: NCT06299007 Completed - Clinical trials for Upper Gastrointestinal Bleeding

Awareness of Iron Status Evaluation in UGIB

AISE
Start date: August 1, 2023
Phase:
Study type: Observational

BACKGROUND: Data on the awareness of the need to evaluate iron status and IDA prevalence in acute UGIB are limited. OBJECTIVES: This study aimed to investigate the rate of evaluation of iron status and prevalence of iron deficiency anemia (IDA) and the associated factors in patients with anemia hospitalized for acute upper gastrointestinal bleeding (UGIB).

NCT ID: NCT06297954 Recruiting - Clinical trials for Upper Gastrointestinal Bleeding

Usefulness of Metoclopramide to Improve Endoscopic Visualization in Upper Gastrointestinal Bleeding

Start date: March 16, 2023
Phase: Phase 3
Study type: Interventional

A prospective, randomized, double-blind study will be conducted, including all patients with upper gastrointestinal bleeding, defined as vomiting blood or black bowel movements, within 12 hours prior to admission. Patients will be randomized to receive intravenous metoclopramide 20 mg or placebo, a placebo is a look-alike substance that contains no active drug. Then endoscopy will be performed in the following 120 minutes, evaluating endoscopic visualization with the modified Avgerinos scale.

NCT ID: NCT06192355 Recruiting - Clinical trials for Upper Gastrointestinal Bleeding

Single-use Versus Reusable Gastroscopes in Patients With Upper Gastrointestinal Bleeding.

OneScopeII
Start date: March 27, 2023
Phase: N/A
Study type: Interventional

Controlled-randomized trial evaluating single-use versus reusable gastroscopes in patients with upper gastrointestinal bleeding.

NCT ID: NCT06077916 Recruiting - Clinical trials for Upper Gastrointestinal Bleeding

Gastric CLEANsing by Intravenous AZithromycin in Urgent Endoscopy

CLEAN-AZ
Start date: October 1, 2023
Phase: N/A
Study type: Interventional

This study will test the hypothesis that azythromycin is efficient and safe in cleansing the upper gastrointestinal tract for endoscopic examination in the case of acute bleeding.

NCT ID: NCT05927493 Completed - Clinical trials for Upper Gastrointestinal Bleeding

Patients With Upper Gastrointestinal Bleeding in Emergency Department

UGIB-ED
Start date: January 1, 2019
Phase:
Study type: Observational

More than 80% of patients with upper gastrointestinal bleeding (UGIB) are hospitalized after their visit to the emergency department (ED). However, some of these hospitalizations do not seem justified. Several clinical scores have been developed to classify patients according to their risk of death or need for therapeutic intervention. The aims of this study are: 1. to describe the characteristics of patients hospitalized for UGIB after their visit to the ED 2. to assess the predictive factors of hospital intervention or death 3. to assess the accuracy of existing prognostic scores to classify patients according their risk of death or need for therapeutic intervention (external validation) and to identify low-risk patients not requiring intervention. 4. Depending on the results, a new score could be derived to identify patients at low risk for intervention or death.

NCT ID: NCT05631652 Completed - Clinical trials for Upper Gastrointestinal Bleeding

Detection of Upper Gastrointestinal (GI) Bleeding Using a Novel Bleeding Sensor Capsule -Healthy Volunteers Study

Start date: February 11, 2021
Phase: N/A
Study type: Interventional

The objective of the investigation is to evaluate the feasibility of detecting blood in healthy volunteers after ingestion of autologous blood mixed with water.

NCT ID: NCT05631639 Completed - Clinical trials for Upper Gastrointestinal Bleeding

Detection of Upper Gastrointestinal (GI) Bleeding Using a Novel Bleeding Sensor Capsule -A Pilot Study

Start date: May 7, 2021
Phase: N/A
Study type: Interventional

This is a multi-center, prospective, non-randomized, open-label, exploratory clinical investigation performed to evaluate safety and effectiveness of the PillSense System when used for detection of blood in the stomach of patients suspected to have an Upper Gastrointestinal Bleed (UGIB).

NCT ID: NCT05563714 Completed - Clinical trials for Upper Gastrointestinal Bleeding

Anticoagulation With Enhanced Gastrointestinal Safety

AEGIS
Start date: October 5, 2022
Phase: N/A
Study type: Interventional

This study is a pragmatic cluster randomized controlled trial to evaluate the effectiveness of a clinician-facing implementation strategy on the use of medication optimization (defined as either discontinuation of all antiplatelet therapy or initiation of and adherence to a proton pump inhibitor (PPI)) to reduce upper GI bleeding risk in patients prescribed anticoagulant-antiplatelet therapy (AAT) relative to usual care.

NCT ID: NCT05385224 Completed - Clinical trials for Upper Gastrointestinal Bleeding

PillSense System for Detecting UGI Bleed

Start date: December 10, 2021
Phase: N/A
Study type: Interventional

This is a prospective, non-randomized, open-label clinical investigation to evaluate feasibility, effectiveness and safety of the PillSense System, the transit of the PillSense Capsule through the GI tract, patient tolerability of the PillSense Capsule, and blood detection.